Guggenheim raises Regeneron stock price target to $975 on Dupixent growth

Guggenheim has increased its price target for Regeneron Pharma (NASDAQ:REGN) to $975 from $865, maintaining a Buy rating, driven by strong Dupixent sales growth of 26% year-over-year. While Dupixent’s success and new approvals are key catalysts, the Eylea franchise experienced a decline in U.S. sales due to competition, though Eylea HD shows potential for renewed growth. Other analysts, including Bernstein, Cantor Fitzgerald, Wells Fargo, and BMO Capital, have also recently updated their ratings and price targets for Regeneron, reflecting varying outlooks on its commercial portfolio and pipeline developments.